NCT04650672 is a clinical trial in Retinal Neovascularization, sponsored by Notal Vision Inc..

Who is sponsoring NCT04650672?

NCT04650672 is sponsored by Notal Vision Inc..

What condition does NCT04650672 study?

NCT04650672 studies Retinal Neovascularization.

Is NCT04650672 still recruiting?

NCT04650672 is currently completed. Last updated 29 November 2021.

Last reviewed 2021-11-29 · How we verify

NCT04650672

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.

Completed Last updated 29 November 2021

What this trial tests

trial in Retinal Neovascularization in 15 participants. Completed in 30 September 2021.

Timeline

8 December 2020

Primary endpoint
4 August 2021

30 September 2021

Quick facts

Lead sponsor	Notal Vision Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	8 December 2020
Primary completion	4 August 2021
Estimated completion	30 September 2021
Sites	2 locations across United States

Conditions studied

Retinal Neovascularization — all drugs for Retinal Neovascularization →

Sponsor

Notal Vision Inc.

Who can join

55 and older, any sex, with Retinal Neovascularization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the ability of subjects with NV-AMD to perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes for 90 days without on-site supervision. The study will include up to 15 subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Retinal Neovascularization

Currently open trials in the same condition.

NCT06595355 — Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin · Phase 2, PHASE3 · recruiting

Other Notal Vision Inc. trials

Trials by the same sponsor.

NCT05690880 — ForeseeHome NRich Registry · active not recruiting
NCT05745116 — Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT · unknown
NCT05650047 — Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD · unknown
NCT05417152 — Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients · completed
NCT05202587 — The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04650672 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Notal Vision Inc.
Last refreshed: 29 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04650672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing